Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Current Deferred Revenue (2016 - 2025)

Collegium Pharmaceutical (COLL) has 7 years of Current Deferred Revenue data on record, last reported at $667000.0 in Q3 2025.

  • For Q3 2025, Current Deferred Revenue fell 97.73% year-over-year to $667000.0; the TTM value through Sep 2025 reached $667000.0, down 97.73%, while the annual FY2023 figure was $20.9 million, 71.56% down from the prior year.
  • Current Deferred Revenue reached $667000.0 in Q3 2025 per COLL's latest filing, down from $172.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $172.4 million in Q2 2025 and bottomed at $667000.0 in Q3 2025.
  • Average Current Deferred Revenue over 5 years is $70.9 million, with a median of $51.5 million recorded in 2022.
  • Peak YoY movement for Current Deferred Revenue: surged 456.13% in 2022, then tumbled 97.73% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $13.2 million in 2021, then soared by 456.13% to $73.6 million in 2022, then plummeted by 71.56% to $20.9 million in 2023, then soared by 40.68% to $29.4 million in 2024, then crashed by 97.73% to $667000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $667000.0 in Q3 2025, $172.4 million in Q2 2025, and $28.1 million in Q1 2025.